ADCYAP1 and migraine disorder: In addition, similarly to CGRP (8), intravenous administration of the 38 amino acid form of PACAP (PACAP1–38) provoked headache and vasodilatation, both in healthy participants and migraine sufferers, whereas it delayed migraine-like attacks only in migraineurs (9–11).